NOVO NORDISK Semaglutide Trial in Children Aged 6 to 11 Hits Endpoint
In the STEP Young phase 3 trial, 40.4% of children treated with semaglutide were no longer classified as having obesity after 68 weeks, versus none on placebo.
In the STEP Young phase 3 trial, 40.4% of children treated with semaglutide were no longer classified as having obesity after 68 weeks, versus none on placebo.